AcuCort resumes recruitment of a permanent CEO
AcuCort AB (Spotlight Stock Market: ACUC) announces today that the recently recruited permanent CEO will not assume his position in the company. For personal reasons, Carl Johan Fredin has chosen to end his employment contract with AcuCort. The company’s interim CEO Ann Gidner will remain in her current position until further notice.
On March 16, 2020 AcuCort announced that the Board of the company had finalized the process to recruit a permanent CEO. The company's new CEO would assume his position at the end of May, which the company now announces will not happen.
“Of course, it is unfortunate that our intended CEO will not assume his position, but sometimes events occur that change ready-made plans and then you have to respect that. In this sudden situation, it is gratifying that Ann Gidner has the possibility to remain in her role as interim CEO until further notice. I also want to take this opportunity and thank Ann Gidner for her very strong contributions during the year as well as for her continued commitment to AcuCort,” says Ebba Fåhraeus, Chairman of the Board of AcuCort AB.
This information is information that AcuCort AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person below, on May 6, 2020.
For further information, please contact
Ebba Fåhraeus, Chairman of the Board, AcuCort AB
Phone: +46 (0)73 400 04 33
About AcuCort AB
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance containing – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe was carried out with positive results and a national hybrid application has been submitted to the Swedish Medical Products Agency. Taken together, this strengthens the company’s assessment that the time until commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Learn more at www.acucort.com.